Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
LONDON - Belluscura plc (AIM:BELL), a UK-based medical device company specializing in oxygen enrichment technology, announced today a strategic review to bolster its financial position and accelerate its path to profitability. This follows a record sales month in April, with revenues reaching $0.52 million driven by strong demand for its X-PLOR portable oxygen concentrator.
The company confirmed that the US import tariff on its products remains at zero, which helps maintain competitive pricing. Despite earlier supply chain issues, Belluscura has seen a surge in demand for the X-PLOR, highlighting a global need for portable oxygen solutions.
Looking ahead, Belluscura anticipates the full commercial launch of its DISCOV-R respiratory support device by the end of Q3, aiming to expand its product lineup.
The strategic review will explore various options, including potential strategic investments, partnerships, and alternative funding structures to improve the company’s capital and working capital position. This initiative is critical as bulk purchasing remains a significant factor in reducing costs, which is a current constraint on the company’s profitability.
As of April 30, 2025, Belluscura reported a cash balance of $1.00 million and a working capital bank debt of $0.79 million. The outcome of the strategic review is uncertain, and the company will provide updates when available. It is noted that the review is not intended to solicit company sale offers under the City Code on Takeovers and Mergers.
This news is based on a press release statement from Belluscura.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.